Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi ( (SNY) ) has issued an update.
On September 4, 2025, Sanofi announced positive results from its COAST 1 phase 3 study, revealing that amlitelimab met all primary and key secondary endpoints in treating moderate-to-severe atopic dermatitis. Amlitelimab, a monoclonal antibody targeting OX40-ligand, showed significant efficacy in skin clearance and disease severity, with potential for dosing only four times a year. These findings highlight amlitelimab’s promise as a differentiated treatment option, supporting Sanofi’s ambition to advance in the atopic dermatitis market.
The most recent analyst rating on (SNY) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score is driven by strong earnings call performance and attractive valuation. Financial stability and profitability are solid, though cash flow constraints and technical indicators suggest caution. The company’s strategic acquisitions and product launches bolster its growth prospects, despite some challenges in specific areas.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is an R&D driven, AI-powered biopharma company focused on improving lives through innovative medicines and vaccines. With a deep understanding of the immune system, Sanofi aims to address urgent healthcare challenges and deliver growth. The company is listed on EURONEXT and NASDAQ.
Average Trading Volume: 2,222,895
Technical Sentiment Signal: Strong Buy
Current Market Cap: $120.1B
See more data about SNY stock on TipRanks’ Stock Analysis page.